NOVO NORDISK A/S |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 912.4 DKK | +1.01% |
|
+0.44% | +30.93% |
| 09:01am | Eli Lilly's diabetes drug tirzepatide gets approval in China | RE |
| 05-20 | US Equity Markets Close Mixed Monday After Fed Officials' Remarks | MT |
Presentation Operator MessageOperator (Operator)Hello, and welcome to the Q2 2020 Novo Nordisk...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
Pharmaceuticals
Calendar
07/08/2024
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
903.3
DKK
Average target price
909.2
DKK
Spread / Average Target
+0.66%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +30.93% | 583B | |
| +34.35% | 705B | |
| -3.49% | 364B | |
| +20.15% | 332B | |
| +6.19% | 291B | |
| +15.30% | 238B | |
| -3.48% | 210B | |
| +10.52% | 209B | |
| +9.21% | 169B | |
| -0.90% | 162B |
- Stock Market
- Equities
- NOVO B Stock
- News Novo Nordisk A/S
- Transcript : Novo Nordisk A/S, Q2 2020 Earnings Call, Aug 06, 2020
